Cost-effectiveness of oral treatments for chronic hepatitis B

Journal of Hepatology

Volumn 51, Issue 4, 2009, Pages 623-625

  Dusheiko, Geoffrey M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEPATITIS B, CHRONIC; HUMANS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS;

EID: 69949171558     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.07.015     Document Type: Editorial

References (10)

1. Buti M., Brosa M., Casado M.A., Rueda M., and Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis. J Hepatol 51 (2009) 640-646
2. Aggarwal R., Ghoshal U.C., and Naik S.R. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Natl Med J India 15 (2002) 320-327
3. Wong J.B. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg 61 (1998) 238-242
4. Crowley S., Tognarini D., Desmond P., Lees M., and Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 17 (2002) 153-164
5. European Association for The Study of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 50 (2009) 227-242
6. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 (2005) 2673-2681
7. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
8. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
9. Fattovich G., Olivari N., Pasino M., D'Onofrio M., Martone E., and Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 57 (2008) 84-90
10. Fattovich G., Bortolotti F., and Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48 (2008) 335-352